After goodbye? Dead hepatocytes as a biomarker for fibrosis and steatohepatitis
Steve Choi, Anna Mae Diehl – 20 December 2011
The end of the beginning for hepatitis C treatment
Douglas Dieterich – 16 December 2011
Safety of the hepatitis E vaccine for pregnant women: A preliminary analysis
Ting Wu, Feng‐Cai Zhu, Shou‐Jie Huang, Xue‐Feng Zhang, Zhong‐Ze Wang, Jun Zhang, Ning‐Shao Xia – 13 December 2011
Acute liver failure: What is it?
Kama A. Wlodzimirow, Saeid Eslami, Ameen Abu‐Hanna, Martin Nieuwoudt, Robert A.F.M. Chamuleau – 12 December 2011
Diagnostic algorithms for liver fibrosis in hepatitis C: Are they ready to avoid liver biopsy?
Giada Sebastiani, Alfredo Alberti – 12 December 2011
Reply:
Jérôme Boursier, Paul Calès – 12 December 2011
An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments
Bryan Cobb, Regis A. Vilchez – 12 December 2011
Is M65 really better than M30 as a biomarker of hepatic fibrosis?
Yusuf Yilmaz, Ramazan Kurt – 12 December 2011
A C‐terminal tyrosine‐based motif in the bile salt export pump directs clathrin‐dependent endocytosis
Ping Lam, Shuhua Xu, Carol J. Soroka, James L. Boyer – 12 December 2011 – The liver‐specific bile salt export pump (BSEP) is crucial for bile acid–dependent bile flow at the apical membrane. BSEP, a member of the family of structurally related adenosine triphosphate (ATP)‐binding cassette (ABC) proteins, is composed of 12 transmembrane segments (TMS) and two large cytoplasmic nucleotide‐binding domains (NBDs).
Reply:
Heike Bantel, Matthias J. Bahr, Jerome Schlue, Klaus Schulze‐Osthoff – 12 December 2011